You Position: Home > Paper
Effects of β1 adrenoceptor antisense on blood pressure and β1 adrenoceptor mRNA and protein in renal hypertension rats
( views:343, downloads:4 )
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF EMERGENCY MEDICINE
- Issue:
- 11
- DOI:
- 10.3760/j.issn:1671-0282.2007.11.009
- Key Word:
- β1受体;两肾一夹肾性高血压;反义寡核苷酸
Abstract： 目的 观察阳离子脂质体混合物与β1受体反义寡核苷酸(β1-AS-ODN)单次注射对两肾一夹肾性高血压大鼠血压及心脏β受体mRNA、受体密度的影响.方法 用SD大鼠制作两肾一夹肾性高血压模型,将动物随机分为5组,每组18只:β1-AS-ODN组,β1-IN-ODN组,2K1C组,假手术组,SD组.于术后第4周经鼠尾静脉注射阳离子脂质体/β1 -ODN的混合物(摩尔比2.0),注射剂量为0.5 mg·kg-1,Tail-cuff法检测血压,半定量RT-PCR测定β1mRNA水平,放射免疫法测定受体密度,Western blot测定蛋白水平.数据采用one-way ANOVA分析,两两比较用Newman-Keuls法.结果 与2K1C组相比,β1-AS-ODN可使血压下降维持4周(P《0.05),可以使血压最大下降39 mmHg;β1-AS-ODN组与高血压组β1受体mRNA水平无明显差异,但β1受体蛋白水平明显降低(P《0.05);与2K1C组比较,注射后第2、7、30天反义组的β1受体水平明显降低, 分别为29.5%、35.5%、20.4% (P《0.01, P《0.01,P《0.05);三组β2受体水平差异无统计学意义.结论 以β1受体为靶基因的反义基因治疗降压效果显著,β1反义寡核苷酸在转录后发挥作用抑制目的 基因表达;β1反义寡核苷酸的降压效果与其特异性地和心脏β1受体结合相关,而与β2受体无关.
- [1]周燕,王晋明,梁远红,等.β1受体基因治疗对肾性高血压大鼠心室重构的影响[J].2005,(3).
- [2]梁远红,王晋明,周燕,等.β1受体反义基因治疗对两肾一夹高血压大鼠血压及血流动力学的影响[J].2004,(10).
- [3]周燕,王晋明,梁远红,等.缬沙坦、螺内酯及其联用对逆转自发性高血压大鼠心肌重塑的影响[J].2005,(1).
- [4]吕雪英,杨云梅,徐哲荣.老年高血压患者血压波动与血管活性物质的相关性[J].2006,(10).
- [5]Olaf, Grisk,Rainer, Rettig.Interactions between the sympathetic nervous system and the kidneys in arterial hypertension.[J].2004,61(2).
- [6]Kokkinos P,Singh S,Chrysohoou C,etc.Beta-blockade mitigates exercise blood pressure in hypertensive male patients.[J].2006,47(4).
- [7]Shant Der Sarkissian,Mohan K. Raizada.Potential of Gene Therapy Strategy for the Treatmentof Hypertension[J].2006,47(1).
- [8]Frédéric, Jacob,Brian G, LaBine,Pilar, Ariza,etc.Renal denervation causes chronic hypotension in rats: role of beta1-adrenoceptor activity.[J].2005,32(4).
- [9]Choi WJ,Park JS,Choi SH,etc.Low toxicity of cationic lipid-based emulsion for gene transfer.[J].2004,25(27).
- [10]Kimura B,Shen L,Clare-Zhang Y,etc.New beta-blocker: prolonged reduction in high blood pressure with beta(1) antisense oligodeoxynucleotides.[J].2000,35(1 Pt.2).